Delivery Order SPE2DE21D7020-SPE2D625F1YAL
- Not listed
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $7,593.10 for EnRoute TCAR stents on August 14, 2025. This fixed-price contract with economic price adjustment is scheduled for ultimate completion by August 21, 2025, and will be performed at Boston Scientific's Marlborough facility. The award is being funded through the Defense Health Agency's Medical Supply Chain, a defense-focused federal...
- Boston Scientific Corp has been awarded a delivery order valued at $3,326.30 for enroute TCAR stents under a Defense Health Agency Medical Supply Chain contract. The award, issued on December 11, 2025, is a fixed-price delivery order with economic price adjustment provisions and carries an ultimate completion date of December 18, 2025. Performance will occur at Boston Scientific's facility in Marlborough, Massachusetts. This delivery order was issued without a small business set-aside,...
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $6,652.60 for enroute TCAR stents on September 26, 2025, with an ultimate completion date of October 3, 2025. This fixed-price contract with economic price adjustment was issued by the Defense Health Agency's Medical Supply Chain division and will be performed in Marlborough, MA. The contract represents no set-aside designation, allowing Boston...
- Boston Scientific Corp, headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $6,652.60 for enroute TCAR stents under a fixed-price contract with economic price adjustment provisions. The award, issued on October 30, 2025, with an ultimate completion date of November 6, 2025, represents a delivery order against an existing contract vehicle with the Defense Health Agency's Medical Supply Chain division. No small business set-aside was utilized for this award,...
- Boston Scientific Corp has been awarded a delivery order valued at $11,389.65 for enroute TCAR stents under a Defense Health Agency Medical Supply Chain contract. The award, issued on September 2, 2025, with an ultimate completion date of September 9, 2025, represents a fixed-price contract with economic price adjustment provisions. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts. No set-aside designation was applied to this award, indicating open...
- Boston Scientific Corp, headquartered in Marlborough, Massachusetts, was awarded a fixed-price delivery order valued at $7,593.10 by the Defense Health Agency's Medical Supply Chain on August 20, 2025, with an ultimate completion date of August 27, 2025. The contract involves the supply of enroute TCAR (transcarotid artery revascularization) stents, specialized cardiovascular intervention devices used in minimally invasive procedures. This delivery order was competitively awarded with no...
- Boston Scientific Corp was awarded a delivery order valued at $3,326.30 by the Defense Health Agency's Medical Supply Chain for enroute TCAR stents, with performance in Marlborough, MA. The contract was awarded on August 12, 2025, with an ultimate completion date of August 19, 2025, and utilizes fixed-price pricing with economic price adjustment. This is an open competition award with no set-aside designation, allowing Boston Scientific to compete directly against other qualified vendors in...
- The Defense Health Agency's Medical Supply Chain awarded a delivery order valued at $3,326.30 to Boston Scientific Corp for EnRoute TCAR stents on July 25, 2025, with an ultimate completion date of August 1, 2025. This fixed-price contract with economic price adjustment carries no set-aside designation, allowing Boston Scientific to compete openly in the federal marketplace. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts, where the company manufactures...
- This federal contract award was issued by the Defense Health Agency (DHA) to Boston Scientific Corp, a global medical technology company headquartered in Marlborough, Massachusetts. The $3,796.55 fixed-price with economic price adjustment delivery order contract is for the provision of ENROUTE TCAR STENTS, which are specialized medical devices used in cardiovascular procedures. The contract has an ultimate completion date of July 16, 2025 and was awarded on July 9, 2025. It is not designated...
- Boston Scientific Corp, a major global medical technology company headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $3,465.00 for an Enroute Introducer Kit, with an ultimate completion date of September 3, 2025. This fixed-price delivery order with economic price adjustment was awarded on August 26, 2025, by the Defense Health Agency's Medical Supply Chain, a defense-focused federal agency responsible for procuring medical devices and equipment for the...
- SPE2DE21D7020Indefinite Delivery Contract
- SPE2DE21D7020-SPE2D625F1YALDelivery Order
Boston Scientific Corp has been awarded a delivery order valued at $14,245.70 for EnRoute TCAR stents under a contract with the Defense Health Agency's Medical Supply Chain on August 26, 2025, with an ultimate completion date of September 3, 2025. This fixed-price contract with economic price adjustment provisions is unset-aside and will be performed at Boston Scientific's facility in Marlborough, Massachusetts. TCAR (Transcarotid Artery Revascularization) stents are specialized cardiovascular intervention devices used in carotid artery treatment, representing part of Boston Scientific's broader portfolio of advanced medical technologies supplied to federal healthcare agencies. This delivery order falls within Boston Scientific's established relationship with the Defense Health Agency and reflects the company's role as a significant supplier of innovative medical devices to federal healthcare systems. As a global medical technology leader, Boston Scientific provides comprehensive cardiovascular and interventional solutions to agencies including the Department of Veterans Affairs and the Defense Logistics Agency. The relatively near-term completion date and modest contract value indicate this is a discrete supply requirement within the company's ongoing support of federal medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 8/26/25 |